Scientists

Compugen Presents Data Update From Ongoing Phase 1 Trial of COM701 at the 2020 AACR Virtual Annual Meeting

Retrieved on: 
Monday, April 27, 2020
Compugen, Anat Cohen-Dayag, Science and technology in Israel, Companies, Scientists

Anat Cohen-Dayag, Ph.D., President and CEO of Compugen, said, "We are thrilled to see durable responses in patients with extremely challenging cancer types with poor prognosis.

Key Points: 
  • Anat Cohen-Dayag, Ph.D., President and CEO of Compugen, said, "We are thrilled to see durable responses in patients with extremely challenging cancer types with poor prognosis.
  • Data from the ongoing study have shown that COM701 is well-tolerated and demonstrated preliminary signals of anti-tumor activity in a heavily pretreated patient population.
  • The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study.
  • Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Adobe Co-Founder Dr. Charles M. Geschke to Retire from Board of Directors

Retrieved on: 
Monday, April 6, 2020
Data management, Technology, Photography, Audio, Video, Software, Internet, Adobe Inc., John Warnock, Companies, Geschke, Scientists, Economy of the United States

Adobe (Nasdaq:ADBE) today announced that Dr. Charles Chuck M. Geschke has notified the company of his decision to not stand for re-election to the Adobe board of directors at the companys 2020 Annual Meeting of Stockholders on April 9, 2020.

Key Points: 
  • Adobe (Nasdaq:ADBE) today announced that Dr. Charles Chuck M. Geschke has notified the company of his decision to not stand for re-election to the Adobe board of directors at the companys 2020 Annual Meeting of Stockholders on April 9, 2020.
  • Dr. Geschke co-founded Adobe in 1982 with Dr. John Warnock, a colleague from Xerox.
  • As much as they were technology innovators, they were also pioneers in creating a progressive and inclusive workplace culture at Adobe.
  • Adobe and the Adobe logo are either registered trademarks or trademarks of Adobe in the United States and/or other countries.

By Breaking Gender Stereotypes, New Innovative Company, Svaha, Empowers Women to Show Off Their Smarts with STEAM-Themed Fashion

Retrieved on: 
Wednesday, March 4, 2020
Programming languages, Scientists, Women, X-ray crystallography, Women in science, Dorothy Hodgkin, Nobel laureates in Physics, Radioactivity, Svaha, Ada Lovelace, Rosalind Franklin, Hodgkin

Thankfully, that is all now changing due to an innovative and trend setting new company called Svaha .

Key Points: 
  • Thankfully, that is all now changing due to an innovative and trend setting new company called Svaha .
  • Each style of dress is named after famous female scientists such as Marie Curie, Rosalind Franklin, Ada Lovelace, Ruby Payne-Scott and Dorothy Hodgkin.
  • She decided that women should not have to choose between loving Science, Technology, Engineering, Art, & Math and being feminine.
  • She turned to Kickstarter yet again, and this time raised over $57K to produce their exclusive line of women's apparel.

Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Engineering

Retrieved on: 
Monday, March 2, 2020
Health, Biotechnology, Laura Niklason, Tissue engineering, Regenerative medicine, Branches of biology, Scientists, Biology

Humacyte, an innovator in biotechnology and regenerative medicine, announced today that company founder, Laura Niklason, M.D., Ph.D., a world leader in tissue engineering and cellular therapies, has been elected to the prestigious National Academy of Engineering (NAE).

Key Points: 
  • Humacyte, an innovator in biotechnology and regenerative medicine, announced today that company founder, Laura Niklason, M.D., Ph.D., a world leader in tissue engineering and cellular therapies, has been elected to the prestigious National Academy of Engineering (NAE).
  • Dr. Niklason was recognized for her major contributions to cardiovascular tissue engineering, lung regeneration and biomedical imaging.
  • Founded in 1964, NAE is an independent, nonprofit institution that provides engineering leadership in service to the nation.
  • It is immensely gratifying to see the distinguished National Academy of Engineering has recognized Laura for her tireless dedication to innovation and leadership in tissue engineering and cellular therapies, said Jeffrey H. Lawson, M.D., Ph.D., President and CEO of Humacyte.

Sigilon Therapeutics to Present at the 40th Annual Cowen & Co. Health Care Conference

Retrieved on: 
Tuesday, February 25, 2020
Biotechnology, Pharmaceutical, Health, Other Health, Lemelson–MIT Prize, Scientists, Robert S. Langer, Science, Awards

Sigilon Therapeutics, Inc., a biotechnology company developing functional cures for chronic diseases through its Shielded Living Therapeutics platform, today announced that Chief Executive Officer Rogerio Vivaldi, M.D., will discuss the companys novel approach to cell therapy and outline upcoming clinical development plans at the 40th Annual Cowen & Co. Health Care Conference in Boston, Massachusetts.

Key Points: 
  • Sigilon Therapeutics, Inc., a biotechnology company developing functional cures for chronic diseases through its Shielded Living Therapeutics platform, today announced that Chief Executive Officer Rogerio Vivaldi, M.D., will discuss the companys novel approach to cell therapy and outline upcoming clinical development plans at the 40th Annual Cowen & Co. Health Care Conference in Boston, Massachusetts.
  • Sigilon expects to initiate a clinical trial of SIG-001 in the first half of 2020.
  • Sigilon Therapeutics is developing functional cures for chronic diseases through its Shielded Living Therapeutics platform.
  • Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Compugen Reports Fourth Quarter and Full Year 2019 Results

Retrieved on: 
Thursday, February 20, 2020
Compugen, Anat Cohen-Dayag, Companies, Science and technology in Israel, Framework Programmes for Research and Technological Development, Holon, Scientists

HOLON, Israel, Feb. 20, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapycompany and a leader in predictive target discovery, today reported financial results for the fourth quarter and full year ended December 31, 2019.

Key Points: 
  • HOLON, Israel, Feb. 20, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapycompany and a leader in predictive target discovery, today reported financial results for the fourth quarter and full year ended December 31, 2019.
  • "2019 was a transformative year for Compugen and we are incredibly proud of the progress we have made in advancing COM701 and COM902," said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen.
  • The Company will hold a conference call today, February 20, 2020, at 8:30 AM ET to review its fourth quarter and full year 2019 results.
  • Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Rosalind Franklin University Announces Research Collaboration With Exicure

Retrieved on: 
Thursday, February 13, 2020
North Chicago, Illinois, Rosalind Franklin University of Medicine and Science, Interprofessional education, Health, Rosalind Franklin, Scientists, Articles

NORTH CHICAGO, Ill., Feb. 13, 2020 /PRNewswire/ --Rosalind Franklin University of Medicine and Science announced today a research collaboration with the Chicagoland biotech company Exicure Inc. to develop new therapeutics for genetic diseases.

Key Points: 
  • NORTH CHICAGO, Ill., Feb. 13, 2020 /PRNewswire/ --Rosalind Franklin University of Medicine and Science announced today a research collaboration with the Chicagoland biotech company Exicure Inc. to develop new therapeutics for genetic diseases.
  • "Tomorrow's treatments begin with today's research," said RFU Executive Vice President for Research Dr. Ronald Kaplan.
  • Our collaboration with Exicure builds on both group's expertise in the field of oligonucleotides as a solution to these often deadly diseases."
  • Rosalind Franklin University of Medicine and Science is committed to serving humanity through the interprofessional education of health and biomedical professionals and the discovery of knowledge dedicated to improving wellness.

KBS Sells Von Karman Tech Center in Irvine, California to a Private Investor for $25.4 Million

Retrieved on: 
Friday, January 24, 2020
Commercial Building & Real Estate, Construction & Property, REIT, California Institute of Technology faculty, Hungarian nobility, Theodore von Kármán, Karman, Irvine, California, Scientists, Science, Engineering

View the full release here: https://www.businesswire.com/news/home/20200124005062/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200124005062/en/
    KBS Sells Von Karman Tech Center to Private Investor for $25.4 Million (Photo: Business Wire)
    The sale represents the strength of assets in the Irvine submarket, according to Rod Richerson, regional president, Western United States for KBS.
  • Von Karman Tech Center was developed in 1980 and fully renovated in 2013-2014.
  • Repositioning activity was prevalent around us during our ownership of Von Karman Tech Center, says Helgeson.
  • Von Karman Tech Center is located at 16842 Von Karman Avenue in Irvine, California.

Beckman Foundation Announces 2020 Beckman Scholars Program Awardees

Retrieved on: 
Thursday, January 16, 2020
Businesspeople, Awards, Arnold Orville Beckman, California Institute of Technology faculty, Beckman, Scientists, Anne Hultgren, Beckman Fellow, Beckman Institute

"We are excited to announce our 2020 Beckman Scholars Program award winners, representing a range of universities from across the country, and including past awardees and new institutions joining the program this year," shared Dr. Anne Hultgren, Executive Director of the Arnold and Mabel Beckman Foundation.

Key Points: 
  • "We are excited to announce our 2020 Beckman Scholars Program award winners, representing a range of universities from across the country, and including past awardees and new institutions joining the program this year," shared Dr. Anne Hultgren, Executive Director of the Arnold and Mabel Beckman Foundation.
  • "The next cohort of Beckman Scholars will start their research projects this summer, and we can't wait to meet them at our upcoming annual Beckman Symposium."
  • The Beckman Scholars Program is a 15-month mentored research experience for exceptional undergraduate students in chemistry, biological sciences and interdisciplinary combinations thereof.
  • Located in Irvine, California, the Arnold and Mabel Beckman Foundation supports researchers and nonprofit research institutions in making the next generation of breakthroughs in chemistry and the life sciences.

Cardiva Medical Appoints Jeri Hilleman to the Company’s Board of Directors

Retrieved on: 
Friday, January 10, 2020
Medical devices, Health, Mumps, Maurice Hilleman, Measles, NASDAQ, Finance, Economy of the United States, Scientists

Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the appointment of medical device expert Jeryl (Jeri) Hilleman to the companys Board of Directors.

Key Points: 
  • Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the appointment of medical device expert Jeryl (Jeri) Hilleman to the companys Board of Directors.
  • Ms. Hilleman currently serves on the board of directors and as audit committee chair of Novocure (Nasdaq: NVCR), Minerva (Nasdaq: NERV) and SI-Bone (Nasdaq: SIBN).
  • Cardiva Medical has emerged as a leader in vascular closure, said Hilleman.
  • VASCADE and Cardiva Catalyst are registered trademarks of Cardiva Medical, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200110005343/en/